Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 1:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 5,920 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Mouth Disease Clear all
Completed Phase 1 Interventional

Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma

NCT00482846
View directory record Official record
Conditions
Mucositis, Multiple Myeloma
Interventions
Palifermin, melphalan, questionnaire administration, autologous peripheral blood stem cell transplantation, quality-of-life assessment
Biological · Drug · Other + 1 more
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 15, 2014 · Synced Oct 28, 2026, 1:04 PM EDT
Completed Phase 2 Interventional Results available

Once-Daily Oral Avatrombopag Tablets Used in Subjects With Chronic Liver Diseases and Thrombocytopenia Prior to Elective Surgical or Diagnostic Procedures

NCT00914927
View directory record Official record
Conditions
Thrombocytopenia Related to Chronic Liver Disease
Interventions
Avatrombopag, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 28, 2026, 1:04 PM EDT
Completed Phase 1 Interventional

A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors

NCT00994071
View directory record Official record
Conditions
Medulloblastoma, Pontine Glioma, Ependymoma, Astrocytoma, PNET
Interventions
Temozolomide, ABT-888
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Oct 28, 2026, 1:04 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Effect of Obesity on Oral Peri-implant Health - A Cross-Sectional Study

NCT01878071
View directory record Official record
Conditions
Obesity, Peri-implant Inflammation, Peri-implantitis
Interventions
Not listed
Lead sponsor
University of Iowa
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2012
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Oct 28, 2026, 1:04 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Role of Oral and Intestinal Microbiota in Rheumatoid Arthritis (RA)

NCT01198509
View directory record Official record
Conditions
Rheumatoid Arthritis, Psoriatic Arthritis, Periodontal Disease
Interventions
doxycycline, vancomycin
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 70 Years
Enrollment
178 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 13, 2015 · Synced Oct 28, 2026, 1:04 PM EDT
Completed Phase 1 Interventional

Study of Two Oral Formulations of LX4211 in Patients With Type 2 Diabetes Mellitus

NCT01188863
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
300 mg LX4211 (150 mg tablets), 300 mg LX4211 (50 mg tablets), 300 mg LX4211 (liquid)
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 30, 2011 · Synced Oct 28, 2026, 1:04 PM EDT
Terminated Phase 2 Interventional

Effect of Oral Propranolol on mRNA Expresssion in Symptomatic Cavernous Malformation

NCT03474614
View directory record Official record
Conditions
Cerebral Cavernous Malformations
Interventions
Propranolol, DNA and RNA Analysis
Drug · Genetic
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 19, 2024 · Synced Oct 28, 2026, 1:04 PM EDT
Terminated Phase 2 Interventional

A Randomized, Dose-ranging Study of Alferon LDO in Asymptomatic HIV+ Subjects

NCT00215852
View directory record Official record
Conditions
HIV Infections
Interventions
Alferon LDO
Drug
Lead sponsor
AIM ImmunoTech Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 4, 2013 · Synced Oct 28, 2026, 1:04 PM EDT
Completed Phase 3 Interventional Results available

Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder (TD)

NCT01418352
View directory record Official record
Conditions
Tourette's Disorder
Interventions
Aripiprazole, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
7 Years to 17 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
13
States / cities
Dothan, Alabama • San Francisco, California • Gainesville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2021 · Synced Oct 28, 2026, 1:04 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Sustained Release Oral Formulation for Treatment of Parkinson's Disease

NCT05471609
View directory record Official record
Conditions
Healthy Volunteers
Interventions
levodopa/carbidopa oral formulation A, levodopa/carbidopa oral formulation B
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 28, 2026, 1:04 PM EDT
Completed Not applicable Interventional

Efficacy & Safety of Submucosal Endoscopic Myotomy With Mucosal Flap (SEMF) in the Treatment of Patients With Achalasia

NCT01438398
View directory record Official record
Conditions
Achalasia, Dysphagia
Interventions
Submucosal endoscopic myotomy with mucosal flap technique, Submucosal Endoscopic Mucosal Flap (SEMF) technique
Procedure
Lead sponsor
Winthrop University Hospital
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Oct 28, 2026, 1:04 PM EDT
Completed Phase 2 Interventional Results available

The Effect of High-dose Silybin-phytosome in Men With Prostate Cancer

NCT00487721
View directory record Official record
Conditions
Prostate Cancer
Interventions
Silibin-Phytosome
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 31, 2014 · Synced Oct 28, 2026, 1:04 PM EDT
Completed Phase 2 Interventional Results available

Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck

NCT01044433
View directory record Official record
Conditions
Head and Neck Cancer, Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Verrucous Carcinoma of the Larynx, Stage IV Verrucous Carcinoma of the Oral Cavity
Interventions
lapatinib ditosylate, capecitabine
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 19, 2020 · Synced Oct 28, 2026, 1:04 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

The Use of Dental Pulp Tissue as an Autogenous Graft for Ridge Augmentation

NCT03943849
View directory record Official record
Conditions
Tooth Loss
Interventions
Particulate bone graft, Autogenous dental pulp tissue, Resorbable collagen membrane, Suture
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 3, 2022 · Synced Oct 28, 2026, 1:04 PM EDT
Completed Not applicable Interventional

Standard Root Planing vs. Periodontal Structure Repair Device for Treatment of Pockets Caused by Periodontal Disease

NCT03671512
View directory record Official record
Conditions
Periodontal Diseases
Interventions
Periodontal Structure Repair (PSR), Standard Root Planing
Device
Lead sponsor
Periovance, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
Birmingham, Alabama • Cambridge, Massachusetts • Stony Brook, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Oct 28, 2026, 1:04 PM EDT
Withdrawn Phase 4 Interventional

Comparison of ARNI to Alternate Oral Vasodilator Therapies in Patients With Low Cardiac Output

NCT04206865
View directory record Official record
Conditions
Cardiogenic Shock
Interventions
Sacubitril-Valsartan, Standard Oral Vasodilators
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Oct 28, 2026, 1:04 PM EDT
Completed Phase 1 Interventional

Safety and Tolerance Study of Oral Doses of CT53518 to Treat Patients With Acute Myelogenous Leukemia (AML)

NCT00064584
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Interventions
CT53518
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
5
States / cities
Los Angeles, California • Boston, Massachusetts • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2009 · Synced Oct 28, 2026, 1:04 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

The Effect of Oral Alpha-Cyclodextrin on Fecal Fat Excretion

NCT01910558
View directory record Official record
Conditions
Obesity, Cardiovascular Disease
Interventions
Alpha-cyclodextrin and digestible starch, Alpha-cyclodextrin, Digestible starch
Dietary Supplement
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 27, 2016 · Synced Oct 28, 2026, 1:04 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Hyaluronidase Via LADD Scleroderma-induced Microstomia

NCT05995626
View directory record Official record
Conditions
Microstomia, Scleroderma
Interventions
Hyaluronidase, CO2 laser
Drug · Device
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
2
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 28, 2026, 1:04 PM EDT
Recruiting Phase 3 Interventional

AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications

NCT07797335
View directory record Official record
Conditions
Type 2 Diabetes, Cardiovascular Risk
Interventions
Zenagamtide, Insulin glargine U-100
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
45 Years and older
Enrollment
1,778 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
109
States / cities
Birmingham, Alabama • Fairhope, Alabama • Montgomery, Alabama + 91 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 28, 2026, 1:04 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Salvage Peanut Oral Immunotherapy Study

NCT03251508
View directory record Official record
Conditions
Peanut Allergy
Interventions
Peanut OIT
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
1 Year to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Oct 28, 2026, 1:04 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study Evaluating the Efficacy and Tolerability of Oral Apremilast for the Treatment of Nail Psoriasis

NCT03022617
View directory record Official record
Conditions
Psoriatic Nail, Psoriasis Vulgaris, Psoriasis
Interventions
Apremilast
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Oct 28, 2026, 1:04 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Controlled Clinical Study to Determine the Gingivitis Benefit of Flossing

NCT00855933
View directory record Official record
Conditions
Gingivitis
Interventions
Experimental Floss
Device
Lead sponsor
Procter and Gamble
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 8, 2013 · Synced Oct 28, 2026, 1:04 PM EDT
Recruiting Phase 3 Interventional

Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient

NCT04268849
View directory record Official record
Conditions
Iron Deficiency Anemia
Interventions
Ferumoxytol, Saline, Ferrous sulfate tablets, Vitamin C
Drug
Lead sponsor
Auerbach Hematology Oncology Associates P C
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 3, 2025 · Synced Oct 28, 2026, 1:04 PM EDT